Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot ApplicableIIT An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of RB001 for the Treatment of SHANK3-related Phelan McDermid Syndrome.
This is a first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of RB001 administered via intracerebroventricular (ICV) injection in pediatric with SHANK3 related Phelan-McDermid Syndrome. Clinical data will be evaluated for safety, tolerability, and preliminary efficacy of RB001 in participants with SHANK3 related PMS.
100 Clinical Results associated with Shenzhen Reborngene Therapeutics Co., Ltd.
0 Patents (Medical) associated with Shenzhen Reborngene Therapeutics Co., Ltd.
100 Deals associated with Shenzhen Reborngene Therapeutics Co., Ltd.
100 Translational Medicine associated with Shenzhen Reborngene Therapeutics Co., Ltd.